ライフサイエンスコーパス: digital ulcer

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ynaud's and skin ulcers, and of bosentan for digital ulcers.

2 ing the effect of treatment on prevention of digital ulcers.

3 ent, or mood, compared with patients without digital ulcers.

4 and frequency of attacks, and resolution of digital ulcers.

5 ary assessments included healing of existing digital ulcers and evaluation of hand function using the

6 bosentan may be effective in preventing new digital ulcers and improving hand function in patients w

7 scales and performed clinical assessments of digital ulcers and infarcts; patients completed the Heal

8 Recurrent digital ulcers are a manifestation of vascular disease i

9 VAS scores for digital ulcers as rated by the patients were not consist

10 daily and stratified according to number of digital ulcers at baseline (</=3 or >3).

11 Fifty-nine patients (21%) had digital ulcers at baseline.

12 patients with systemic sclerosis and active digital ulcers at baseline.

13 Patients who had digital ulcers at the time of entry in the study were at

14 imary outcome variable was the number of new digital ulcers developing during the 16-week study perio

15 rs and (for those with recurrent SSc-related digital ulcers) endothelin-1 receptor antagonism.

16 each trial was the cumulative number of new digital ulcers from baseline to week 16.

17 The VAS for digital ulcers, GI symptoms, and lung symptoms correlate

18 Patients with digital ulcers had worse RCS, pain, HAQ disability (over

19 , bosentan, decreased the development of new digital ulcers in patients with SSc.

20 Digital ulcers in patients with systemic sclerosis are a

21 ty, pain, and psychological impact of RP and digital ulcers in SSc can be measured by a small set of

22 t the use of macitentan for the treatment of digital ulcers in this patient population.

23 mber of new systemic sclerosis (SSc)-related digital ulcers in two multinational clinical trials; and

24 and physician VAS ratings of RP activity, a digital ulcer/infarct measure, measures of disability an

25 inct domains: disease activity, RP measures, digital ulcer measures, and mood/tension.

26 The presence of new digital ulcers or improvement in digital ulcers showed s

27 able effects on the occurrence of upper limb digital ulcers or on other vascular manifestations of lc

28 Quinapril did not affect the occurrence of digital ulcers or the frequency or severity of RP episod

29 treatment with macitentan did not reduce new digital ulcers over 16 weeks.

30 The adjusted mean number of new digital ulcers per patient over 16 weeks was 0.94 in the

31 ence of new digital ulcers or improvement in digital ulcers showed significant associations with the

32 with systemic sclerosis and active ischemic digital ulcers, treatment with macitentan did not reduce

33 In DUAL-2, the adjusted mean number of new digital ulcers was 1.44 in the 3-mg macitentan group (n

34 rity of the Raynaud phenomenon and fewer new digital ulcers were seen in the epoprostenol group.

35 mited versus diffuse), or number of baseline digital ulcers were taken into account.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。